- Open Access
Induction of complement proteins in a mouse model for cerebral microvascular Aβ deposition
© Fan et al; licensee BioMed Central Ltd. 2007
- Received: 30 July 2007
- Accepted: 18 September 2007
- Published: 18 September 2007
The deposition of amyloid β-protein (Aβ) in cerebral vasculature, known as cerebral amyloid angiopathy (CAA), is a common pathological feature of Alzheimer's disease and related disorders. In familial forms of CAA single mutations in the Aβ peptide have been linked to the increase of vascular Aβ deposits accompanied by a strong localized activation of glial cells and elevated expression of neuroinflammatory mediators including complement proteins. We have developed human amyloid-β precursor protein transgenic mice harboring two CAA Aβ mutations (Dutch E693Q and Iowa D694N) that mimic the prevalent cerebral microvascular Aβ deposition observed in those patients, and the Swedish mutations (K670N/M671L) to increase Aβ production. In these Tg-SwDI mice, we have reported predominant fibrillar Aβ along microvessels in the thalamic region and diffuse plaques in cortical region. Concurrently, activated microglia and reactive astrocytes have been detected primarily in association with fibrillar cerebral microvascular Aβ in this model. Here we show that three native complement components in classical and alternative complement pathways, C1q, C3, and C4, are elevated in Tg-SwDI mice in regions rich in fibrillar microvascular Aβ. Immunohistochemical staining of all three proteins was increased in thalamus, hippocampus, and subiculum, but not frontal cortex. Western blot analysis showed significant increases of all three proteins in the thalamic region (with hippocampus) as well as the cortical region, except C3 that was below detection level in cortex. Also, in the thalamic region (with hippocampus), C1q and C3 mRNAs were significantly up-regulated. These complement proteins appeared to be expressed largely by activated microglial cells associated with the fibrillar microvascular Aβ deposits. Our findings demonstrate that Tg-SwDI mice exhibit elevated complement protein expression in response to fibrillar vascular Aβ deposition that is observed in patients with familial CAA.
- Cerebral Amyloid Angiopathy
- Complement Protein
- Thalamic Region
- Compromise Blood Brain Barrier
- Fibrillar Amyloid Deposit
Abnormal accumulation of amyloid β peptides (Aβ) in brain is one of the major pathological characterizations of Alzheimer's disease (AD) and related disorders . Aβ, a 39–42 residue proteolytic product of the amyloid-β peptide precursor (AβPP) by β- and γ-secretase cleavages, possesses a high propensity to self-assemble into β sheet-rich fibrils . One prominent site of brain Aβ deposition is in and along the walls of cerebral blood vessels, a condition known as cerebral amyloid angiopathy (CAA), which is frequently found in AD [3, 4]. In contrast to parenchymal plaques, which can be composed of either diffuse or fibrillar deposits, cerebral vascular Aβ deposits appear to be exclusively fibrillar in nature . Several familial forms of CAA result from specific point mutations within the mid-region of the Aβ domain, which significantly enhance the fibrillogenic and cerebral vascular cytotoxic properties of Aβ [6–8].
Previously, we generated transgenic mice that express neuronally derived human AβPP, containing the Dutch-type (E693Q) and Iowa-type (D694N) familial CAA mutations, the Tg-SwDI mice . These mice were shown to develop early-onset and robust deposition of cerebral microvascular fibrillar amyloid but only diffuse parenchymal Aβ plaques. The microvascular accumulation of fibrillar Aβ is most prominent in the thalamic and subiculum regions of the brain . In these areas with the most fibrillar microvascular Aβ deposits, activated inflammatory cells, microglia and astrocytes, were also found highly enhanced . Several pro-inflammatory cytokines were shown to be elevated in Tg-SwDI mouse brains, indicating the active synthesis of inflammatory molecules by these cells [10, 11].
Another important aspect of the neuroinflammatory response in AD and CAA is the innate immune system activation, among which, complement is a key player . Complement proteins have been shown to be induced and associated with Aβ plaques in brains of AD patients and familial CAA patients as well as AD animal models, specifically those plaques containing the fibrillar form of the Aβ peptide [13–15]. The overall outcome of complement activation depends on the balance of its detrimental and beneficial effects . On one side, complement activation could induce cell lysis and cause cell death [17, 18]; on the other side, complement components such as C1q and C3b can promote the clearance of cellular debris and apoptotic cells and enhance cell survival [15, 19]. Although complement proteins are typically secreted by immune cells, in the CNS, microglia, astrocytes, and neurons have been reported being capable of producing complement components upon stimulation [20, 21]. In the current study, we investigated the expression of several native complement components in twelve months old Tg-SwDI and wild-type C57BL/6 mice, and found they were increased significantly in association with microvascular amyloid deposits and co-localized with activated microglial cells. The finding that microglial synthesis of the native complement proteins was induced suggests that early complement activation may be increased in the Tg-SwDI mouse model of cerebral microvacular Aβ deposition.
Generation of Tg-SwDI transgenic mice on a pure C57BL/6 background was recently described . These mice express low levels of human Swedish/Dutch/Iowa mutant AβPP in neurons under control of the mouse Thy1.2 promoter. The deposition of mutant Dutch/Iowa Aβ peptide starts around 3 months of age and begins to plateau at about 15 months in transgenic mice with low variation between individuals. Homozygous Tg-SwDI and nontransgenic C57BL/6 mice at 12 months of age were used in this study. All work with animals followed National Institutes of Health guidelines and was approved by Stony Brook University Institutional Animal Care and Use Committee.
At least 24 mice per genotype were euthanized at 12 months of age. After cold-phosphate buffer saline (PBS, 0.1M, pH 7.6) perfusion, brains were removed and dissected through the mid-sagittal plane. One cerebral hemisphere was immersion-fixed with 4% paraformaldehyde overnight at 4°C and subjected to increasing concentrations (10, 20, and 30%) of sucrose in PBS, then embedded in OCT compound (Sakura Finetek Inc., Torrance, CA) and snap-frozen in dry ice. Coronal sections were cut at 20-μm thickness using a Leica CM1900 cryostat (Leica Microsystems, Inc., Bannockburn, IL), and then stored in PBS with 0.02% NaN3 at 4°C.
Immunostainings were performed on sections mounted on Colorfrost/Plus slides (Fisher Scientific, Houston, TX). Antigen retrieval was performed in 1:100 antigen-unmasking solution (Vector Lab, Burlingame, CA) for 30 min at 90°C for C1q and microglia immunostaining. Nonspecific binding was prevented by incubating sections in blocking buffer (PBS containing 0.1% Triton X-100 and 2% bovine serum albumin (Sigma, St. Louis, MO) for 20 min at room temperature. Brain sections were incubated with primary antibodies diluted in blocking buffer overnight at 4°C. The following primary antibodies were used for immunostaining: mouse monoclonal antibody to glial fibrillary acidic protein (GFAP) for identification of astrocytes (1:300, Millipore, Temecula, CA); mouse monoclonal antibody 5D4 to keratan sulfate for identification of activated microglia (1:300; Seikagaku Corporation, Japan); monoclonal rat-anti-mouse C3 (1:500) and monoclonal rat-anti-mouse C4 (1:1000, Cedarlane, Burlington, NC); polyclonal rabbit-anti-mouse C1q (1:500, generous gift from Dr. Andrea J Tenner, University of California, Irvine). Biotinylated donkey anti-rat IgG and donkey anti-rabbit IgG (both at 1:200, Vector Lab), followed by Fluor590-conjugated streptavidin (1:500, Invitrogen, Carlsbad, CA) and Fluor488-conjugated anti-mouse antibody (1:500, Invitrogen) were used for immuno-detection.
The brain sections were examined using an Olympus BX60 fluorescent microscope (Olympus America Inc., Center Valley, PA) with Olympus DP10 camera (Olympus) and ASI MS-2000 motorized stage (Applied Scientific Instruments, Eugene, OR). Pictures were taken with 10x eye-piece and 40x objective.
Micro-dissected tissue was removed from the thalamic (with hippocampus) and cortical (frontal cortex) brain regions of 12-months old Tg-SwDI and non-transgenic (C57BL/6) mice (from the other hemisphere of the same animals used for histology). Half of each group were homogenized on ice in lysis buffer containing 1% SDS, 0.5% IGPEL in PBS with Complete protease inhibitor (Roche, Basel, Switzerland) at 10 ml/g tissue ratio. The protein concentration was determined using the bichinchonic acid method (Pierce, Rockford, IL). Equal amounts of protein (50 μg) were loaded, fractionated on 10% SDS-polyacrylamide gels, and subsequently electrophoretically transferred to nitrocellulose membranes (Schleicher and Schuell, Hertogen-bosch, Netherlands) in blotting buffer (25 mM Tris-HCl, pH 8.6, 192 mM glycine, and 20% methanol). Blots were washed for 15 min in PBS containing 0.05% Tween 20 (PBST), pre-incubated with blocking solution (5% non-fat milk powder in PBST), washed three times with PBST, and subsequently incubated with primary antibodies and peroxidase-labeled secondary goat anti-rat or donkey anti-rabbit antibodies (Dako, Glostrup, Denmark). Detection was performed by chemiluminescence according to the description of the manufacturer (Boehringer Mannheim, Almere, Netherlands) and exposed to Kodak (Rochester, NY) X-OMAT-R films and quantified using VersaDoc imaging system (BioRad, Hercules, CA). The molecular mass of specific bands was determined by comparing to the BenchMark pre-stained protein ladder (Invitrogen) electrophoresed on the same gels.
Real-time reverse transcriptase polymerase chain reaction
Total RNA was isolated from the tissue using RNeasy Lipid Tissue Kit (Qiagen, Hilden, Germany) as per manufacturer's instructions. Single stranded cDNA was prepared using 10 μl of total RNA using iScript cDNA Synthesis Kit (Biorad) per manufacturer's instructions. 6-carboxyfluorescein (FAM) 5' end labeled Taqman Assay on Demand primer and probe sets (Applied Biosystems, Foster City, CA) were used to assess expression levels of C1q (Mm00437836_m1) and C3 (Mm01232773_m1) for each cDNA sample. All samples were normalized against the endogenous control, TATA box binding protein (Mm00446973_m1). 500 ng of each cDNA sample was used in conjunction with 8 pmoles of each primer/probe set plus Taqman Universal Master Mix (Applied Biosystems). Each sample was analyzed in triplicates. Real-time quantitative PCR was performed on an Opticon2 (Biorad) using the following program: 95°C for 10 sec, followed by 40 cycles of denaturation, 95°C for 15 sec and anneal/elongation, 60°C for 1 min. The relative expression level of C1q or C3 was computed with respect to the mRNA expression of the endogenous control using the following formula: Relative mRNA expression = 2-(-Ct gene of interest-Ct TATA)
Biochemical and molecular data were analyzed by ANOVA single factor test at α = 0.05 significance level.
C1q, C3, and C4 were induced in Tg-SwDI mice
Complement proteins are synthesized in Tg-SwDI mouse brain
Complement proteins are expressed in activated microglia of Tg-SwDI mice
We have reported before that in Tg-SwDI mice, in spite of the low expression level of transgene encoded human AβPP, profuse fibrillar amyloid deposits were present in cerebral microvessels, likely due to the highly fibrillogenic property of the Dutch/Iowa CAA mutant Aβ peptide, with no detectable export of this Aβ into the periphery . In association with the microvascular fibrillar Aβ deposits, reactive microglia and astrocytes were found in these animals, and increased with age in parallel to the microvascular Aβ deposition . We also detected pro-inflammatory cytokines such as TNFα, IL-1β, and IL-6 to be enhanced in Tg-SwDI mice, suggesting that these activated cells are actively expressing inflammatory molecules surrounding the microvasculature [10, 11]. Previously, it has been shown that complement components are induced in AD patients and familial CAA patients as well as brains of AD animal models . In addition to the well-studied pathogen elimination by complement activation, amyloid clearance may be promoted by C1q binding to fibrillar amyloid deposits, and generation of an opsonin, the C3b fragment [15, 25]. Human studies have also shown increasing complement staining with growing presence of CAA . However, due to the inefficient binding of mouse C1q to human Aβ, complement activation is much less in mouse models for AD than in AD patients , which might explain why we did not observe the presence of late-stage complement activation products. In brain, activated microglia are the major source of complement proteins in brain, although reactive astrocytes and neurons have also been shown to express complement when stimulated [28, 29].
Here we demonstrate that early native classical complements C1q and C4, as well as C3, an important player in both classical and alternative complement pathways, are up-regulated in Tg-SwDI mouse brains. This induction was likely due to local synthesis since we have detected the increase in messenger RNA and protein levels by real-time PCR technique and Western blot, respectively. The observed differences between mRNA and protein levels of C1q and C3 were possibly due to several reasons. For example, increased levels of certain complement proteins may reflect decreased turnover and/or accumulation with amyloid deposits in the absence of increased expression. Also, the sensitivities of real-time PCR and Western blot are different depending on primers and antibodies, and the message levels may not be translated linearly to protein expression.
The immunoreactivities of C1q, C3, and C4 were cell associated and appeared to track along cerebral microvascular amyloid deposits, particularly in thalamus and subiculum (data not shown). We then investigated the cell type that expressed the complement. Double immunofluorescent labeling indicated that most complement-positive cells were activated microglia, not astrocytes. Although not all complement-positive cells overlapped with activated microglial labeling, this was possibly due to the multiple activation stages and types of microglia and one activation marker (keratan sulfate in this case [30, 31] may not reflect all activated microglial cells. These findings further support the notion that microglia in the Tg-SwDI mouse model are actively participating in the neuroinflammatory response and provide more insight into the specific reactions of microglia during disease progression as well as modulations of these reactions. In light of our recent work in which we detected improvement of memory performance in animals when microglial activation was suppressed , the effect of that inhibition on complement induction remains to be investigated to further elucidate the function of elevated complement in this model.
In summary, complement proteins C1q, C3, and C4 were induced in Tg-SwDI mice in proximity to the cerebral microvasculature. This increase in expression was primarily in thalamus and hippocampus, and also in subiculum by immunohistochemistry (data not shown), regions that contain the highest amount of fibrillar microvascular amyloid deposition. These complement proteins were locally synthesized in brain, and mostly by activated microglial cells associated with microvascular Aβ deposits.
This work is supported by NIH grants NS55118 and NS36645. The authors thank Ms. Judianne Davis for her input in modifying real-time PCR protocols and Dr. Feng Xu for helping with collecting animal brains. Special thanks to Dr. Andrea J. Tenner at University of California, Irvine for providing the anti-C1q antibody.
- Walsh DM, Selkoe DJ: Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron. 2004, 44 (1): 181-193. 10.1016/j.neuron.2004.09.010.View ArticlePubMedGoogle Scholar
- Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (New York, NY. 2002, 297 (5580): 353-356.View ArticleGoogle Scholar
- Wilcock DM, Gordon MN, Morgan D: Quantification of cerebral amyloid angiopathy and parenchymal amyloid plaques with Congo red histochemical stain. Nature protocols. 2006, 1 (3): 1591-1595. 10.1038/nprot.2006.277.View ArticlePubMedGoogle Scholar
- Attems J, Quass M, Jellinger KA, Lintner F: Topographical distribution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. Journal of the neurological sciences. 2007, 257 (1-2): 49-55. 10.1016/j.jns.2007.01.013.View ArticlePubMedGoogle Scholar
- Revesz T, Ghiso J, Lashley T, Plant G, Rostagno A, Frangione B, Holton JL: Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. Journal of neuropathology and experimental neurology. 2003, 62 (9): 885-898.PubMedGoogle Scholar
- Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GT, Luyendijk W, Frangione B: Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science (New York, NY. 1990, 248 (4959): 1124-1126.View ArticleGoogle Scholar
- Levy E, Haltia M, Fernandez-Madrid I, Koivunen O, Ghiso J, Prelli F, Frangione B: Mutation in gelsolin gene in Finnish hereditary amyloidosis. The Journal of experimental medicine. 1990, 172 (6): 1865-1867. 10.1084/jem.172.6.1865.View ArticlePubMedGoogle Scholar
- Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM: Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Annals of neurology. 2001, 49 (6): 697-705. 10.1002/ana.1009.View ArticlePubMedGoogle Scholar
- Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, Van Nostrand WE: Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. The Journal of biological chemistry. 2004, 279 (19): 20296-20306. 10.1074/jbc.M312946200.View ArticlePubMedGoogle Scholar
- Miao J, Xu F, Davis J, Otte-Holler I, Verbeek MM, Van Nostrand WE: Cerebral microvascular amyloid beta protein deposition induces vascular degeneration and neuroinflammation in transgenic mice expressing human vasculotropic mutant amyloid beta precursor protein. The American journal of pathology. 2005, 167 (2): 505-515.PubMed CentralView ArticlePubMedGoogle Scholar
- Fan R, Xu F, Previti ML, Davis J, Grande AM, Robinson JK, Van Nostrand WE: Minocycline reduces microglial activation and improves behavioral deficits in a transgenic model of cerebral microvascular amyloid. J Neurosci. 2007, 27 (12): 3057-3063. 10.1523/JNEUROSCI.4371-06.2007.View ArticlePubMedGoogle Scholar
- McGeer EG, McGeer PL: Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. Molecular interventions. 2001, 1 (1): 22-29.PubMedGoogle Scholar
- Strohmeyer R, Shen Y, Rogers J: Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain research. 2000, 81 (1-2): 7-18. 10.1016/S0169-328X(00)00149-2.View ArticlePubMedGoogle Scholar
- Yasojima K, Schwab C, McGeer EG, McGeer PL: Up-regulated production and activation of the complement system in Alzheimer's disease brain. The American journal of pathology. 1999, 154 (3): 927-936.PubMed CentralView ArticlePubMedGoogle Scholar
- Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E: Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proceedings of the National Academy of Sciences of the United States of America. 2002, 99 (16): 10837-10842. 10.1073/pnas.162350199.PubMed CentralView ArticlePubMedGoogle Scholar
- Shen Y, Meri S: Yin and Yang: complement activation and regulation in Alzheimer's disease. Progress in neurobiology. 2003, 70 (6): 463-472.View ArticlePubMedGoogle Scholar
- Fonseca MI, Zhou J, Botto M, Tenner AJ: Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci. 2004, 24 (29): 6457-6465. 10.1523/JNEUROSCI.0901-04.2004.View ArticlePubMedGoogle Scholar
- Shen Y, Halperin JA, Benzaquen L, Lee CM: Characterization of neuronal cell death induced by complement activation. Brain research. 1997, 1 (2): 186-194.PubMedGoogle Scholar
- Rus H, Cudrici C, Niculescu F, Shin ML: Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection. Journal of neuroimmunology. 2006, 180 (1-2): 9-16. 10.1016/j.jneuroim.2006.07.009.View ArticlePubMedGoogle Scholar
- Shen Y, Li R, McGeer EG, McGeer PL: Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain research. 1997, 769 (2): 391-395. 10.1016/S0006-8993(97)00850-0.View ArticlePubMedGoogle Scholar
- Stoltzner SE, Grenfell TJ, Mori C, Wisniewski KE, Wisniewski TM, Selkoe DJ, Lemere CA: Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. The American journal of pathology. 2000, 156 (2): 489-499.PubMed CentralView ArticlePubMedGoogle Scholar
- Sundaresan S, Roberts PE, King KL, Sliwkowski MX, Mather JP: Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. Endocrinology. 1998, 139 (12): 4756-4764. 10.1210/en.139.12.4756.View ArticlePubMedGoogle Scholar
- Heid CA, Stevens J, Livak KJ, Williams PM: Real time quantitative PCR. Genome research. 1996, 6 (10): 986-994. 10.1101/gr.6.10.986.View ArticlePubMedGoogle Scholar
- Eikelenboom P, van Gool WA: Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J Neural Transm. 2004, 111 (3): 281-294. 10.1007/s00702-003-0055-1.View ArticlePubMedGoogle Scholar
- Webster SD, Yang AJ, Margol L, Garzon-Rodriguez W, Glabe CG, Tenner AJ: Complement component C1q modulates the phagocytosis of Abeta by microglia. Experimental neurology. 2000, 161 (1): 127-138. 10.1006/exnr.1999.7260.View ArticlePubMedGoogle Scholar
- Tanskanen M, Lindsberg PJ, Tienari PJ, Polvikoski T, Sulkava R, Verkkoniemi A, Rastas S, Paetau A, Kiuru-Enari S: Cerebral amyloid angiopathy in a 95+ cohort: complement activation and apolipoprotein E (ApoE) genotype. Neuropathology and applied neurobiology. 2005, 31 (6): 589-599. 10.1111/j.1365-2990.2005.00652.x.View ArticlePubMedGoogle Scholar
- Webster SD, Tenner AJ, Poulos TL, Cribbs DH: The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation. Neurobiology of aging. 1999, 20 (3): 297-304. 10.1016/S0197-4580(99)00020-2.View ArticlePubMedGoogle Scholar
- Afagh A, Cummings BJ, Cribbs DH, Cotman CW, Tenner AJ: Localization and cell association of C1q in Alzheimer's disease brain. Experimental neurology. 1996, 138 (1): 22-32. 10.1006/exnr.1996.0043.View ArticlePubMedGoogle Scholar
- Terai K, Walker DG, McGeer EG, McGeer PL: Neurons express proteins of the classical complement pathway in Alzheimer disease. Brain research. 1997, 769 (2): 385-390. 10.1016/S0006-8993(97)00849-4.View ArticlePubMedGoogle Scholar
- Thiex R, Mayfrank L, Rohde V, Gilsbach JM, Tsirka SA: The role of endogenous versus exogenous tPA on edema formation in murine ICH. Exp Neurol. 2004, 189: 25-32. 10.1016/j.expneurol.2004.05.021.View ArticlePubMedGoogle Scholar
- Stichel CC, Niermann H, D'Urso D, Lausberg F, Hermanns S, Muller HW: Basal membrane-depleted scar in lesioned CNS: characteristics and relationships with regenerating axons. Neuroscience. 1999, 93: 321-333. 10.1016/S0306-4522(99)00112-8.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.